Company Profile
Spero Therapeutics Stock Price, News & Catalysts
- Ticker:
- SPRO
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
1.12 USD (+0.90%)
Close
Last updated: September 17, 2026
164M USD
Market cap
Why the stock is moving
As of Sep 17, 2026, SPRO closed up 0.90% at $1.12. No new same-company headline was identified in the current news window.
Company overview
Immunology and Inflammation Company
Spero Therapeutics is a clinical-stage biopharmaceutical company developing medicines for serious immune-mediated diseases. Its internal strategy now centers on CD40 ligand inhibition.
SP001
SP001 is a third-generation, Fc-silent monoclonal antibody targeting CD40 ligand. The molecule is designed to suppress pathogenic immune-cell interactions while reducing the platelet-activation concerns associated with earlier anti-CD40L antibodies.
IgG4-Related Disease
Spero plans to develop SP001 first in IgG4-related disease, a rare chronic fibroinflammatory disorder that can damage multiple organs. The company also sees potential applications across additional immunologic and inflammatory diseases.
Utebzi Economics
Utebzi is an FDA-approved oral carbapenem antibiotic for certain adults with complicated urinary tract infections, including pyelonephritis. GSK controls U.S. and European commercialization, while Spero retains exposure to milestones and royalties.
Future catalysts
- U.S. commercial availability of Utebzi through GSK by the end of 2026.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Spero Therapeutics (SPRO)?
Spero Therapeutics (SPRO) most recently closed at 1.12 USD, a +0.90% move versus the previous session.
What is the market cap of Spero Therapeutics (SPRO)?
Spero Therapeutics currently has a market capitalization of 164M USD on BioPharmSignal.
What does Spero Therapeutics do?
Immunology and Inflammation Company Spero Therapeutics is a clinical-stage biopharmaceutical company developing medicines for serious immune-mediated diseases. Its internal strategy now centers on CD40 ligand inhibition. SP001 SP001 is a third-generation, Fc-silent monoclonal antibody targeting CD40 ligand. The molecule is designed to suppress pathogenic...
On which exchange is SPRO stock listed?
Spero Therapeutics (SPRO) is associated with NASDAQ, United States, Biopharma.
What is Immunology?
Immunology and Inflammation Company Spero Therapeutics is a clinical-stage biopharmaceutical company developing medicines for serious immune-mediated diseases.
Which conditions is Spero Therapeutics targeting with Immunology?
Spero Therapeutics is associated with immunology, inflammatory disease based on its company overview and current catalyst commentary.
How does Spero Therapeutics describe recent progress with Immunology?
U.S. commercial availability of Utebzi through GSK by the end of 2026.
What is Inflammation?
Immunology and Inflammation Company Spero Therapeutics is a clinical-stage biopharmaceutical company developing medicines for serious immune-mediated diseases.